[
	{
		"ID": "1",
		"Drug": "tolterodine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7801#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7801#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122519#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology, Drug Interactions, Warnings and Precautions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237932.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237932.htm#",
		"FDA_Referenced_Subgroup_2": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_2": "Warnings and Precautions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology",
		"FDA_Link_2": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm397104.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm397104.htm#",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA164746757#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "2",
		"Drug": "tramadol",
		"Gene_Pair": "CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7795#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7795#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122516#",
		"Substrates": "CYP2D6 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237933.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237933.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451735#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "3",
		"Drug": "trimipramine",
		"Gene_Pair": "CYP2C19;CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7829#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7829#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122525#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267396.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267396.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451791#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "4",
		"Drug": "venlafaxine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7862#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7862#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122530#",
		"Substrates": "CYP2D6 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm238042.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm238042.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451866#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "5",
		"Drug": "voriconazole",
		"Gene_Pair": "CYP2C19",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3385141#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3385141#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122535#",
		"Substrates": "CYP2C19 ",
		"Inducers": "",
		"Inhibitors": "CYP2B6 ,CYP2C9 ,CYP2C19 ,CYP3A4, CYP3A5, & CYP3A7",
		"FDA_Referenced_Subgroup_1": "CYP219 intermediate or poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology, Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm238044.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm238044.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA10233#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "6",
		"Drug": "vortioxetine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/4720782#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/4720782#",
		"Eformulary_link_Pharmacogenomics": "",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Dosage and Administration, Drug interactions, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm397142.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm397142.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "",
		"Guideline_1": "FDA",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "7",
		"Drug": "warfarin",
		"Gene_Pair": "CYP2C9;CYP4F2;VKORC1",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3385126#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3385126#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122536#",
		"Substrates": "CYP1A2, CYP2C9, CYP2C19",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2C9 intermediate or poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Dosage and Administration, Drug Interactions, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm238046.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm238046.htm#",
		"FDA_Referenced_Subgroup_2": "VKORC1 rs9923231 A allele carriers",
		"FDA_Relevant_Labeling_Sections_2": "Dosage and Administration, Clinical Pharmacology",
		"FDA_Link_2": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm238050.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm238050.htm#",
		"PharmGKB_Link": "https://www.pharmgkb.org/drug/PA451906",
		"Guideline_1": "CPIC",
		"Guideline_2": "FDA",
		"Guideline_3": "FDA",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "8",
		"Drug": "zuclopenthixol",
		"Gene_Pair": "CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7903",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122542#",
		"Substrates": "CYP2D6 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA452629#",
		"Guideline_1": "DPWG",
		"Guideline_2": "DPWG",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "39",
		"Drug": "abacavir",
		"Gene_Pair": "HLA-B*57:01",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3361659#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3361659#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122077#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "HLA-B*5701 allele carriers",
		"FDA_Relevant_Labeling_Sections_1": "Boxed Warning, Contraindications, Warnings and Precautions, Patient Counseling Information",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm226174.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm226174.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA448004#",
		"Guideline_1": "CPIC",
		"Guideline_2": "DPWG",
		"Guideline_3": "FDA",
		"Guideline_4": "",
		"Risk_Information": "Risk of carrying HLA-B*57:01: 3%\r\n\r\nPopulation Risk for HSR is 5-8 % of exposed patients\r\nHSR risk for HLA-B*57:01 - approximately 50%"
	},
	{
		"ID": "40",
		"Drug": "acenocoumarol",
		"Gene_Pair": "CYP2C9;VKORC1",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/150061#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/150061#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/1152639#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA452632#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "41",
		"Drug": "allopurinol",
		"Gene_Pair": "HLA-B*58:01",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3361899#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3361899#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122087#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA448320#",
		"Guideline_1": "CPIC",
		"Guideline_2": "PRO",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "42",
		"Drug": "amitriptyline",
		"Gene_Pair": "CYP2C19;CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452473#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452473#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/pated_f/400464#",
		"Substrates": "CYP1A2, CYP2C9, CYP2C19, CYP2D6",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Precautions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm372273.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm372273.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA448385#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "43",
		"Drug": "second generation antipsychotics",
		"Gene_Pair": "ANKK1",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "",
		"Eformulary_link_Pharmacogenomics": "",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "",
		"Guideline_1": "",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": "Heterozygotes: \r\nPatient is 1.3 times more likely to experience tardive dyskinesia (OR = 1.30)\r\n\r\nHomozygotes: \r\nPatient is 1.5 times more likely to experience tardive dyskinesia (OR = 1.50)"
	},
	{
		"ID": "44",
		"Drug": "aripiprazole",
		"Gene_Pair": "CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6384#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6384#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122103#",
		"Substrates": "CYP3A4, CYP3A5, & CYP3A7, CYP2D6",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology, Dosage and Administration",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236063.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236063.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA10026#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "45",
		"Drug": "atomoxetine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6398#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6398#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122108#",
		"Substrates": "CYP2D6 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Dosage and Administration, Warnings and Precautions, Drug Interactions, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236090.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236090.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA134688071#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "46",
		"Drug": "azathioprine",
		"Gene_Pair": "TPMT",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3366976#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3366976#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122109#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "TPMT intermediate or poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Dosage and Administration, Warnings and Precautions, Drug Interactions, Adverse Reactions, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236181.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236181.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA448515#",
		"Guideline_1": "CPIC",
		"Guideline_2": "DPWG",
		"Guideline_3": "FDA",
		"Guideline_4": "",
		"Risk_Information": "Normal Metabolizer: ~ 86-97% of population\r\n\r\nIntermediate Metabolizer: ~ 3-14% of population\r\n~30-60% will experience myelosuppression at conventional dosing\r\n\r\nPoor Metabolizer: ~ 1% of population\r\n~100% will experience life threatening myelosuppression at conventional dosing"
	},
	{
		"ID": "47",
		"Drug": "boceprevir",
		"Gene_Pair": "IFNL3",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/3439545#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/3439545#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/3597202#",
		"Substrates": "CYP3A4, CYP3A5, & CYP3A7 ",
		"Inducers": "",
		"Inhibitors": "CYP3A4, CYP3A5, & CYP3A7",
		"FDA_Referenced_Subgroup_1": "IL28B rs12979860 T allele carriers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm256294.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm256294.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA165948902#",
		"Guideline_1": "CPIC",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": "Favorable Response:\r\n90% chance of SVR after 24-48 weeks\r\n80-90% of patients are eligible for shortened treatment (medication dependent)\r\n\r\nUnfavorable Response:\r\n60% chance of SVR after 24-48 weeks\r\n50% of patients are eligible for shortened treatment (medication dependent)"
	},
	{
		"ID": "48",
		"Drug": "bupropion",
		"Gene_Pair": "ANKK1",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6485#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6485#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122128#",
		"Substrates": "CYP2B6 ",
		"Inducers": "",
		"Inhibitors": "CYP2D6 (Strong)",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA448687#",
		"Guideline_1": "",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "49",
		"Drug": "capecitabine",
		"Gene_Pair": "DPYD",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6519#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6519#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122135#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "DPD deficient",
		"FDA_Relevant_Labeling_Sections_1": "Contraindications, Warnings and Precautions, Patient Information",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236253.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236253.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA448771#",
		"Guideline_1": "CPIC",
		"Guideline_2": "DPWG",
		"Guideline_3": "FDA",
		"Guideline_4": "",
		"Risk_Information": "Normal Metabolizers:  95-97 % of patients\r\n~ 10-40% are at risk for severe toxicity\r\n\r\nIntermediate Metabolizers: 3-5% of patients\r\nPoor Metabolizers: 0.2 % of patients\r\n\r\nPPV: ~50-62%  NPV: ~90%\r\n50-62% of patients with reduced function variants in DPYD will have severe reactions at conventional doses"
	},
	{
		"ID": "50",
		"Drug": "carbamazepine",
		"Gene_Pair": "HLA-A*31:01;HLA-B*15:02",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3369260#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3369260#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122137#",
		"Substrates": "CYP3A4, CYP3A5, & CYP3A7 ",
		"Inducers": "CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, & CYP3A7 ",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "HLA-B*1502 allele carriers",
		"FDA_Relevant_Labeling_Sections_1": "Boxed Warning, Warnings and Precautions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236254.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236254.htm#",
		"FDA_Referenced_Subgroup_2": "HLA-A*3101 allele carriers",
		"FDA_Relevant_Labeling_Sections_2": "Boxed Warning, Warnings and Precautions",
		"FDA_Link_2": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm372156.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm372156.htm#",
		"PharmGKB_Link": "https://www.pharmgkb.org/drug/PA448785",
		"Guideline_1": "CPIC",
		"Guideline_2": "FDA",
		"Guideline_3": "PRO",
		"Guideline_4": "",
		"Risk_Information": "HLA-B*15:02\r\nHan Chinese: \r\nHLA-B*15:02 carrier rate is 15.3-19.8% in population\r\nHLA-B*15:02 carrier rate is 63% in all SJS/TEN cases\r\n\r\nPatient is 38.6 times more likely to develop SJS/TEN (OR = 38.65) than non-carrier population\r\n\r\nHLA-A*31:01\r\nRisk for HSS or MPE:  patient is 26.3 times and 8.57 times more likely to experience HSS or MPE (respectively) than non-carriers"
	},
	{
		"ID": "51",
		"Drug": "carisoprodol",
		"Gene_Pair": "CYP2C19",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6540#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6540#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122139#",
		"Substrates": "CYP2C19 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2C19 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology, Special Populations",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm266929.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm266929.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "https://www.pharmgkb.org/drug/PA448809",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "52",
		"Drug": "carvedilol",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3369262#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3369262#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122141#",
		"Substrates": "CYP2D6 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236255.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236255.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA448817#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "53",
		"Drug": "celecoxib",
		"Gene_Pair": "CYP2C9",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6565#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6565#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122144#",
		"Substrates": "CYP2C9 ",
		"Inducers": "",
		"Inhibitors": "CYP2D6",
		"FDA_Referenced_Subgroup_1": "CYP2C9 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Dosage and Administration, Drug Interactions, Use in Specific Populations, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236256.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236256.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA448871#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "54",
		"Drug": "cevimeline",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6578#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6578#",
		"Eformulary_link_Pharmacogenomics": "",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236276.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236276.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA164754754#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "55",
		"Drug": "cisplatin",
		"Gene_Pair": "TMEM43/XPC",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452359#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452359#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122158#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "TPMT intermediate or poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology, Warnings, Precautions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm287714.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm287714.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449014#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "56",
		"Drug": "citalopram",
		"Gene_Pair": "CYP2C19;CYP2D6;GRIK4",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3369277#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3369277#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122159#",
		"Substrates": "CYP2C19 ",
		"Inducers": "",
		"Inhibitors": "CYP2D6",
		"FDA_Referenced_Subgroup_1": "CYP2C19 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions, Warnings",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267567.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267567.htm#",
		"FDA_Referenced_Subgroup_2": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_2": "Drug Interactions",
		"FDA_Link_2": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267568.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267568.htm#",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449015#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": "GRIK4:\r\nFavorable Response: Reduces risk of non-response to citalopram by 11% \r\n\r\nUnfavorable Response: 11% less likely to respond to citalopram than C-allele carriers"
	},
	{
		"ID": "57",
		"Drug": "clobazam",
		"Gene_Pair": "CYP2C19",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3369303#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3369303#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122163#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2C19 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology, Dosage and Administration, Use in Specific Populations",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm278224.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm278224.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA10888#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "58",
		"Drug": "clomipramine",
		"Gene_Pair": "CYP2C19;CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452472#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452472#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122166#",
		"Substrates": "CYP1A2, CYP2C19, CYP2D6",
		"Inducers": "",
		"Inhibitors": "CYP2D6",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267576.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267576.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449048#",
		"Guideline_1": "CPIC",
		"Guideline_2": "DPWG",
		"Guideline_3": "FDA",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "59",
		"Drug": "clopidogrel",
		"Gene_Pair": "CYP2C19",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3369307#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3369307#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122169#",
		"Substrates": "CYP2C19 ",
		"Inducers": "",
		"Inhibitors": "CYP2B6",
		"FDA_Referenced_Subgroup_1": "CYP2C19 intermediate or poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Boxed Warning, Dosage and Administration, Warnings and Precautions, Drug Interactions, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236280.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236280.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449053#",
		"Guideline_1": "CPIC",
		"Guideline_2": "DPWG",
		"Guideline_3": "FDA",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "60",
		"Drug": "clozapine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6649#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6649#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122171#",
		"Substrates": "CYP1A2 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236282.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236282.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449061#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "61",
		"Drug": "codeine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6653#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6653#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122173#",
		"Substrates": "CYP2D6, CYP3A4, CYP3A5, & CYP3A7",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 Ultra-rapid metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Boxed Warnings, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology , Patient Counseling Information",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm397154.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm397154.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449088#",
		"Guideline_1": "CPIC",
		"Guideline_2": "DPWG",
		"Guideline_3": "FDA",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "62",
		"Drug": "desipramine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452471#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452471#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122182#",
		"Substrates": "CYP2D6 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267045.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267045.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449233#",
		"Guideline_1": "CPIC",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "63",
		"Drug": "dexlansoprazole",
		"Gene_Pair": "CYP2C19",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/1658719#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/1658719\\#",
		"Eformulary_link_Pharmacogenomics": "",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2C19 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology, Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm262875.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm262875.htm#",
		"FDA_Referenced_Subgroup_2": "CYP1A2 genotypes",
		"FDA_Relevant_Labeling_Sections_2": "Clinical Pharmacology",
		"FDA_Link_2": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267055.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267055.htm#",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA166110257#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "64",
		"Drug": "dextromethorphan and quinidine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/2940100#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/2940100#",
		"Eformulary_link_Pharmacogenomics": "",
		"Substrates": "CYP2D6, CYP3A4, CYP3A5, & CYP3A7",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology, Warnings and Precautions, Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm238561.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm238561.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449273#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "65",
		"Drug": "diazepam",
		"Gene_Pair": "CYP2C19",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3378024#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3378024#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/pated_f/400748#",
		"Substrates": "CYP2C19, CYP3A4, CYP3A5, & CYP3A7",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2C19 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236311.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236311.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449283#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "66",
		"Drug": "doxepin",
		"Gene_Pair": "CYP2C19;CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/1827021#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/1827021#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/2139761#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "CYP2D6",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Precautions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236325.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236325.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449409#",
		"Guideline_1": "CPIC",
		"Guideline_2": "DPWG",
		"Guideline_3": "FDA",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "67",
		"Drug": "drospirenone and ethinyl estradiol",
		"Gene_Pair": "CYP2C19",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6799#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6799#",
		"Eformulary_link_Pharmacogenomics": "",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2C19 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology, Warnings and Precautions, Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236328.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236328.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/label/PA166104814#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "68",
		"Drug": "duloxetine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6798#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6798#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/1153441#",
		"Substrates": "CYP1A2, CYP2D6",
		"Inducers": "",
		"Inhibitors": "CYP2D6 (Moderate)",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA10066#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "69",
		"Drug": "escitalopram",
		"Gene_Pair": "CYP2C19",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6846#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6846#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122221#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "CYP2D6",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA10074#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "70",
		"Drug": "esomeprazole",
		"Gene_Pair": "CYP2C19",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3001039#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3001039#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122223#",
		"Substrates": "CYP2C19 ",
		"Inducers": "",
		"Inhibitors": "CYP2C19",
		"FDA_Referenced_Subgroup_1": "CYP2C19 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236406.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236406.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA10075#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "71",
		"Drug": "flecainide",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3416841#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3416841#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122250#",
		"Substrates": "CYP2D6 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449646#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "72",
		"Drug": "fluorouracil",
		"Gene_Pair": "DPYD",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452370#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452370#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/2139773#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "DPD deficient",
		"FDA_Relevant_Labeling_Sections_1": "Contraindications, Warnings, Patient Information",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236410.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236410.htm#",
		"FDA_Referenced_Subgroup_2": "DPD deficient",
		"FDA_Relevant_Labeling_Sections_2": "Warnings",
		"FDA_Link_2": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm357551.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm357551.htm#",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA128406956#",
		"Guideline_1": "CPIC",
		"Guideline_2": "DPWG",
		"Guideline_3": "FDA",
		"Guideline_4": "",
		"Risk_Information": "Normal Metabolizers:  95-97 % of patients\r\n~ 10-40% are at risk for severe toxicity\r\n\r\nIntermediate Metabolizers: 3-5% of patients\r\nPoor Metabolizers: 0.2 % of patients\r\n\r\nPPV: ~50-62%  NPV: ~90%\r\n50-62% of patients with reduced function variants in DPYD will have severe reactions at conventional doses"
	},
	{
		"ID": "73",
		"Drug": "fluoxetine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3416844#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3416844#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122253#",
		"Substrates": "CYP2C9, CYP2D6",
		"Inducers": "",
		"Inhibitors": "CYP2C19 ,CYP2D6 (Strong)",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Warnings, Precautions, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236420.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236420.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449673#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "74",
		"Drug": "flupenthixol",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6933#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6933#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122254#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA10268#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "75",
		"Drug": "flurbiprofen",
		"Gene_Pair": "CYP2C9",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/1797302#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/1797302#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/2139775#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2C9 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology, Special Populations",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm265687.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm265687.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449683#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "76",
		"Drug": "fluvoxamine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6942#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6942#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122262#",
		"Substrates": "CYP1A2, CYP2D6",
		"Inducers": "",
		"Inhibitors": "CYP1A2 (Strong) ,CYP1A2 ,CYP2C9 ,CYP2C19 ,CYP3A4, CYP3A5, & CYP3A7",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267074.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267074.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449690#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "77",
		"Drug": "galantamine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6964#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6964#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122270#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Special Populations",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267175.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267175.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449726#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "78",
		"Drug": "glibenclamide",
		"Gene_Pair": "CYP2C9",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6988#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6988#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122276#",
		"Substrates": "CYP2C9 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449782#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "79",
		"Drug": "gliclazide",
		"Gene_Pair": "CYP2C9",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6979#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6979#",
		"Eformulary_link_Pharmacogenomics": "",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA10892#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "80",
		"Drug": "glimepiride",
		"Gene_Pair": "CYP2C9",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6980#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6980#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122274#",
		"Substrates": "CYP2C9 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449761#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "81",
		"Drug": "haloperidol",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3433663#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3433663#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122281#",
		"Substrates": "CYP1A2, CYP2D6, CYP3A4, CYP3A5, & CYP3A7",
		"Inducers": "",
		"Inhibitors": "CYP2D6",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449841#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "82",
		"Drug": "hormonal contraceptives for systemic use",
		"Gene_Pair": "F5",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "",
		"Eformulary_link_Pharmacogenomics": "",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA452637#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "83",
		"Drug": "iloperidone",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/1731499#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/1731499#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/3456864#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology, Dosage and Administration, Drug Interactions, Specific Populations, Warnings and Precautions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267303.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267303.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA161199368#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "84",
		"Drug": "imipramine",
		"Gene_Pair": "CYP2C19;CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452470#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452470#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122297#",
		"Substrates": "CYP1A2, CYP2C19, CYP2D6",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267581.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267581.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA449969#",
		"Guideline_1": "CPIC",
		"Guideline_2": "DPWG",
		"Guideline_3": "FDA",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "85",
		"Drug": "indacaterol",
		"Gene_Pair": "UGT1A1",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/3479346#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/3479346#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/3616082#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "UGT1A1 *28 allele homozygotes",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm283068.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm283068.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "https://www.pharmgkb.org/drug/PA165958348",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "86",
		"Drug": "irinotecan",
		"Gene_Pair": "UGT1A1",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452427#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452427#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122303#",
		"Substrates": "OATP1B1/SLCO1B1, CYP3A4, CYP3A5, & CYP3A7 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "UGT1A1*28 allele carriers",
		"FDA_Relevant_Labeling_Sections_1": "Dosage and Administration, Warnings, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236793.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236793.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450085#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "87",
		"Drug": "ivacaftor",
		"Gene_Pair": "CFTR",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/3636103#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/3636103#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/3695263#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CFTR G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R carriers",
		"FDA_Relevant_Labeling_Sections_1": "Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm290088.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm290088.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA165950341#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "88",
		"Drug": "lansoprazole",
		"Gene_Pair": "CYP2C19",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3435838#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3435838#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122314#",
		"Substrates": "CYP2C19 ",
		"Inducers": "",
		"Inhibitors": "CYP2C19",
		"FDA_Referenced_Subgroup_1": "CYP2C19 poor metabolizer",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm338077.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm338077.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450180#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "89",
		"Drug": "mercaptopurine",
		"Gene_Pair": "TPMT",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452423#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452423#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122343#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "TPMT intermediate or poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Dosage and Administration, Contraindications, Precautions, Adverse Reactions, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236814.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236814.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450379#",
		"Guideline_1": "CPIC",
		"Guideline_2": "DPWG",
		"Guideline_3": "FDA",
		"Guideline_4": "",
		"Risk_Information": "Normal Metabolizer: ~ 86-97% of population\r\n\r\nIntermediate Metabolizer: ~ 3-14% of population\r\n~30-60% will experience myelosuppression at conventional dosing\r\n\r\n\r\nPoor Metabolizer: ~ 1% of population\r\n~100% will experience life threatening myelosuppression at conventional dosing"
	},
	{
		"ID": "90",
		"Drug": "methotrexate",
		"Gene_Pair": "MTHFR",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3439572#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3439572#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/3388659#",
		"Substrates": "OATP1B1/SLCO1B1",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450428#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "91",
		"Drug": "metoprolol",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3435580#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3435580#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122359#",
		"Substrates": "CYP2D6 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Precautions, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236819.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236819.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450480#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "92",
		"Drug": "mirtazapine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7305#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7305#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122365#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450522#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "93",
		"Drug": "moclobemide",
		"Gene_Pair": "CYP2C19",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7309#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7309#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122367#",
		"Substrates": "CYP2C19 ",
		"Inducers": "",
		"Inhibitors": "CYP2D6",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA452615#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "94",
		"Drug": "modafinil",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7312#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7312#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122368#",
		"Substrates": "",
		"Inducers": "CYP1A2, CYP3A4, CYP3A5, & CYP3A7 ",
		"Inhibitors": "CYP2C19",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267315.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267315.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450530#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "95",
		"Drug": "nefazodone",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7350#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7350#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122383#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "CYP3A4, CYP3A5, & CYP3A7 (Strong)",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm268751.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm268751.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "https://www.pharmgkb.org/drug/PA450603",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "96",
		"Drug": "nortriptyline",
		"Gene_Pair": "CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7385#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7385#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122395#",
		"Substrates": "CYP2D6 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267362.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267362.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450657#",
		"Guideline_1": "CPIC",
		"Guideline_2": "DPWG",
		"Guideline_3": "FDA",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "97",
		"Drug": "olanzapine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3407240#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3407240#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122398#",
		"Substrates": "CYP1A2 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450688#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "98",
		"Drug": "omeprazole",
		"Gene_Pair": "CYP2C19",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3002822#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3002822#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122401#",
		"Substrates": "CYP2C19 ",
		"Inducers": "CYP1A2 ",
		"Inhibitors": "CYP2C19",
		"FDA_Referenced_Subgroup_1": "CYP2C19 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Dosage and Administration, Warnings and Precautions, Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm283066.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm283066.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450704#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "99",
		"Drug": "oxycodone",
		"Gene_Pair": "CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3407245#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3407245#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122405#",
		"Substrates": "CYP2D6 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450741#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "100",
		"Drug": "pantoprazole",
		"Gene_Pair": "CYP2C19",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3002825#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3002825#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122410#",
		"Substrates": "CYP2C19 ",
		"Inducers": "",
		"Inhibitors": "CYP2C19",
		"FDA_Referenced_Subgroup_1": "CYP2C19 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology, Drug Interactions, Special Populations",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267371.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267371.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450774#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "101",
		"Drug": "paroxetine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7442#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7442#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122412#",
		"Substrates": "CYP2D6 ",
		"Inducers": "",
		"Inhibitors": "CYP2C9 ,CYP2D6 (Strong)",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology, Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267381.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267381.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450801#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "102",
		"Drug": "peginterferon-alfa-2a",
		"Gene_Pair": "IFNL3",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7447#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7447#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/3597165#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "IL28B rs12979860 T allele carriers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm256296.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm256296.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA164749390#",
		"Guideline_1": "CPIC",
		"Guideline_2": "DPWG",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": "Favorable Response:\r\n90% chance of SVR after 24-48 weeks\r\n80-90% of patients are eligible for shortened treatment (medication dependent)\r\n\r\nUnfavorable Response:\r\n60% chance of SVR after 24-48 weeks\r\n50% of patients are eligible for shortened treatment (medication dependent)"
	},
	{
		"ID": "103",
		"Drug": "peginterferon-alfa-2b",
		"Gene_Pair": "IFNL3",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7448#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7448#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/3597182#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "IL28B rs12979860 T allele carriers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm256296.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm256296.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA164784024#",
		"Guideline_1": "CPIC",
		"Guideline_2": "DPWG",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": "Favorable Response:\r\n90% chance of SVR after 24-48 weeks\r\n80-90% of patients are eligible for shortened treatment (medication dependent)\r\n\r\nUnfavorable Response:\r\n60% chance of SVR after 24-48 weeks\r\n50% of patients are eligible for shortened treatment (medication dependent)"
	},
	{
		"ID": "104",
		"Drug": "perphenazine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7472#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7472#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122418#",
		"Substrates": "CYP2D6 ",
		"Inducers": "",
		"Inhibitors": "CYP2D6",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology, Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267726.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm267726.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450882#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "105",
		"Drug": "phenytoin",
		"Gene_Pair": "CYP2C9;HLA-B*15:02",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3003239#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3003239#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122421#",
		"Substrates": "CYP2C9, CYP2C19",
		"Inducers": "CYP2B6, CYP3A4, CYP3A5, & CYP3A7 ",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "HLA-B*1502 allele carriers",
		"FDA_Relevant_Labeling_Sections_1": "Warnings",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm280936.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm280936.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450947#",
		"Guideline_1": "CPIC",
		"Guideline_2": "DPWG",
		"Guideline_3": "FDA",
		"Guideline_4": "",
		"Risk_Information": "Han Chinese: \r\nHLA-B*15:02 carrier rate is 15.3-19.8% in population\r\n HLA-B*15:02 carrier rate is 63% in all SJS/TEN cases\r\n\r\nPatient is 3.5 times more likely to develop SJS/TEN (OR = 3.50) than non-carrier population"
	},
	{
		"ID": "106",
		"Drug": "pimozide",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7494#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7494#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122422#",
		"Substrates": "CYP3A4, CYP3A5, & CYP3A7 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Warnings, Precautions, Contraindications, Dosage and Administration",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm274355.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm274355.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450965#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "107",
		"Drug": "prasugrel",
		"Gene_Pair": "CYP2C19",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/1803419#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/1803419#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/3654303#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2C19 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Use in Specific Populations, Clinical Pharmacology, Clinical Studies",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm265500.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm265500.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA154410481#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "108",
		"Drug": "propafenone",
		"Gene_Pair": "CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3406799#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3406799#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122437#",
		"Substrates": "CYP2D6 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237478.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237478.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451131#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "109",
		"Drug": "propranolol",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3003319#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3003319#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122441#",
		"Substrates": "CYP1A2, CYP2C19, CYP2D6, CYP3A4, CYP3A5, & CYP3A7",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Precautions, Drug Interactions, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237480.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237480.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451145#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "110",
		"Drug": "protriptyline",
		"Gene_Pair": "CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7582#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7582#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122442#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Precautions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237483.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237483.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451168#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "111",
		"Drug": "quinidine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7601#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7601#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122445#",
		"Substrates": "CYP3A4, CYP3A5, & CYP3A7 ",
		"Inducers": "",
		"Inhibitors": "CYP2D6 (Strong)",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Precautions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237501.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237501.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451209#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "112",
		"Drug": "rabeprazole",
		"Gene_Pair": "CYP2C19",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7604#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7604#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122447#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2C19 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237503.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237503.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451216#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "113",
		"Drug": "rasburicase",
		"Gene_Pair": "G6PD",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3402053#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3402053#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122452#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA10176#",
		"Guideline_1": "CPIC",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "114",
		"Drug": "ribavirin",
		"Gene_Pair": "IFNL3",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3415490#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3415490#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/3597183#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451241#",
		"Guideline_1": "CPIC",
		"Guideline_2": "DPWG",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": "Favorable Response:\r\n90% chance of SVR after 24-48 weeks\r\n80-90% of patients are eligible for shortened treatment (medication dependent)\r\n\r\nUnfavorable Response:\r\n60% chance of SVR after 24-48 weeks\r\n50% of patients are eligible for shortened treatment (medication dependent)"
	},
	{
		"ID": "115",
		"Drug": "risperidone",
		"Gene_Pair": "CYP2D6",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3402052#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3402052#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122460#",
		"Substrates": "CYP2D6, CYP3A4, CYP3A5, & CYP3A7",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237637.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237637.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451257#",
		"Guideline_1": "DPWG",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "116",
		"Drug": "sertraline",
		"Gene_Pair": "CYP2C19",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3402048#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3402048#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122470#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "CYP2C9 ,CYP2D6 (Moderate)",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451333#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "117",
		"Drug": "simvastatin",
		"Gene_Pair": "SLCO1B1",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7671#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7671#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122475#",
		"Substrates": "OATP1B1/SLCO1B1, CYP3A4, CYP3A5, & CYP3A7 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451363#",
		"Guideline_1": "CPIC",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": "Population myopathy risk - 1-5% of exposed individuals\r\n\r\n40mg\r\nIntermediate risk: Patient is 2.6 times more likely to develop myopathy\r\nHigh risk: Patient is 5.2 times more likely to develop myopathy\r\n\r\n80mg \r\nIntermediate risk: Patient is 4.5 times more likely to develop myopathy\r\nHigh risk: Pateint is approximately 20 times more likely to develop myopathy"
	},
	{
		"ID": "118",
		"Drug": "tacrolimus",
		"Gene_Pair": "CYP3A5",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3385181#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3385181#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/2139820#",
		"Substrates": "CYP3A4, CYP3A5, & CYP3A7 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451578#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "119",
		"Drug": "tamoxifen",
		"Gene_Pair": "CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7724#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7724#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122492#",
		"Substrates": "CYP2C9, CYP2D6, CYP3A4, CYP3A5, & CYP3A7",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451581#",
		"Guideline_1": "DPWG",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "120",
		"Drug": "tegafur",
		"Gene_Pair": "DPYD",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7847#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7847#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/4647254#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA452620#",
		"Guideline_1": "CPIC",
		"Guideline_2": "DPWG",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": "Normal Metabolizers:  95-97 % of patients\r\n~ 10-40% are at risk for severe toxicity\r\n\r\nIntermediate Metabolizers: 3-5% of patients\r\nPoor Metabolizers: 0.2 % of patients\r\n\r\nPPV: ~50-62%  NPV: ~90%\r\n50-62% of patients with reduced function variants in DPYD will have severe reactions at conventional doses"
	},
	{
		"ID": "121",
		"Drug": "telaprevir",
		"Gene_Pair": "IFNL3",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/3445779#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/3445779#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/3597203#",
		"Substrates": "CYP3A4, CYP3A5, & CYP3A7 ",
		"Inducers": "",
		"Inhibitors": "CYP3A4, CYP3A5, & CYP3A7",
		"FDA_Referenced_Subgroup_1": "IL28B rs12979860 T allele carriers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm256307.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm256307.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA165958354#",
		"Guideline_1": "CPIC",
		"Guideline_2": "FDA",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": "Favorable Response:\r\n90% chance of SVR after 24-48 weeks\r\n80-90% of patients are eligible for shortened treatment (medication dependent)\r\n\r\nUnfavorable Response:\r\n60% chance of SVR after 24-48 weeks\r\n50% of patients are eligible for shortened treatment (medication dependent)"
	},
	{
		"ID": "122",
		"Drug": "terbinafine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/751#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/751#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/2139822#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "CYP2D6 (Moderate)",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Drug Interactions",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237723.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237723.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451614#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "123",
		"Drug": "tetrabenazine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/150063#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/150063#",
		"Eformulary_link_Pharmacogenomics": "",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Dosage and Administration, Warnings, Clinical Pharmacology",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237725.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237725.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA140222719#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "124",
		"Drug": "thioguanine",
		"Gene_Pair": "TPMT",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452438#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3452438#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122503#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "TPMT poor metabolizer",
		"FDA_Relevant_Labeling_Sections_1": "Dosage and Administration, Precautions, Warnings",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237732.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237732.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451663#",
		"Guideline_1": "CPIC",
		"Guideline_2": "DPWG",
		"Guideline_3": "FDA",
		"Guideline_4": "",
		"Risk_Information": "Normal Metabolizer: ~ 86-97% of population\r\n\r\nIntermediate Metabolizer: ~ 3-14% of population\r\n~30-60% will experience myelosuppression at conventional dosing\r\n\r\n\r\nPoor Metabolizer: ~ 1% of population\r\n~100% will experience life threatening myelosuppression at conventional dosing"
	},
	{
		"ID": "125",
		"Drug": "thioridazine",
		"Gene_Pair": "CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7759#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7759#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122504#",
		"Substrates": "CYP2D6 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2D6 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Precautions, Warnings, Contraindications",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237921.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm237921.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451666#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "126",
		"Drug": "ticagrelor",
		"Gene_Pair": "CYP2C19",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/3452307#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/3452307#",
		"Eformulary_link_Pharmacogenomics": "",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "CYP2C19 poor metabolizers",
		"FDA_Relevant_Labeling_Sections_1": "Clinical Studies",
		"FDA_Link_1": "http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm265501.htm#http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm265501.htm#",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA165374673#",
		"Guideline_1": "FDA",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "127",
		"Drug": "tolbutamide",
		"Gene_Pair": "CYP2C19",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7785#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7785#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122512#",
		"Substrates": "CYP2C9 ",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA451718#",
		"Guideline_1": "",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "128",
		"Drug": "isoniazid",
		"Gene_Pair": "NAT2",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3435830#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/122304#",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450112#",
		"Guideline_1": "",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "129",
		"Drug": "ondansetron",
		"Gene_Pair": "CYP2D6",
		"Clinical": "3",
		"Eformulary_link_Drug_Monograph": "#http://online.lexi.com/lco/action/doc/retrieve/docid/sickkids_f/3407241#",
		"Eformulary_link_Pharmacogenomics": "#http://online.lexi.com/lco/action/doc/retrieve/docid/genom_f/1259824#",
		"Substrates": "CYP1A2, CYP2D6, CYP3A4, CYP3A5, & CYP3A7",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA450705#",
		"Guideline_1": "",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "130",
		"Drug": "cerivastatin",
		"Gene_Pair": "SLCO1B1",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "#http://online.lexi.com/lco/action/doc/retrieve/docid/fc_fms/4791803#",
		"Eformulary_link_Pharmacogenomics": "",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "#https://www.pharmgkb.org/drug/PA448897#",
		"Guideline_1": "",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	},
	{
		"ID": "131",
		"Drug": "statins",
		"Gene_Pair": "SLCO1B1",
		"Clinical": "2",
		"Eformulary_link_Drug_Monograph": "#http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/4258#",
		"Eformulary_link_Pharmacogenomics": "",
		"Substrates": "",
		"Inducers": "",
		"Inhibitors": "",
		"FDA_Referenced_Subgroup_1": "",
		"FDA_Relevant_Labeling_Sections_1": "",
		"FDA_Link_1": "",
		"FDA_Referenced_Subgroup_2": "",
		"FDA_Relevant_Labeling_Sections_2": "",
		"FDA_Link_2": "",
		"PharmGKB_Link": "",
		"Guideline_1": "",
		"Guideline_2": "",
		"Guideline_3": "",
		"Guideline_4": "",
		"Risk_Information": ""
	}
]